

## ANSWERING REVIEWERS



April 16, 2019

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 47141-Edited.doc).

**Title:** Modified FOLFIRINOX for resected pancreatic cancer: opportunities and challenges

**Author:** Feng Yang, Chen Jin, Deliang Fu, Andrew L. Warshaw

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 47141

The manuscript has been improved according to the suggestions of reviewers and our answers appear in red in the text.

1 Format has been updated.

2 Revision has been made according to the suggestions of the reviewer:

**Reviewer 1:** All his/her suggestions have been considered.

(1) The manuscript reviews modified FOLFIRINOX for resected pancreatic cancer. This is an up-to-date and well-written review/ commentary. I would suggest to additionally mention and discuss the APAC trial. Otherwise, I can recommend this manuscript for publication..□□□□

**Answer:** We highly appreciate the reviewer's comment and good suggestion. In the revision, we have discussed the APAC trial in the penultimate paragraph. "... It is worth noting that both modified FOLFIRINOX and nab-paclitaxel plus gemcitabine have been established as standard first-line treatment for metastatic pancreatic cancer, showing comparable efficacy outcomes [32]. The APACT trial is a phase III, international, multicenter, randomized, open-label, controlled study to compare adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with surgically resected pancreatic cancer (ClinicalTrials.gov, NCT01964430). 866 patients have been randomized in 1:1 ratio to receive 6 cycles of either nab-paclitaxel 125 mg/m<sup>2</sup> plus gemcitabine 1000 mg/m<sup>2</sup> or gemcitabine alone 1000 mg/m<sup>2</sup> on days 1, 8, and 15 of a 4-week cycle. The preliminary results will be announced in the near future, and provide us further evidence for adjuvant treatment for resected pancreatic cancer."

### Reference

[32] Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. *Invest New Drugs*. 2018;36(4):732-741. [PMID 29616439 DOI: 10.1007/s10637-018-0598-5]

### Reviewer 2:

(1) I read with care the manuscript titled "Modified FOLFIRINOX for resected pancreatic cancer: opportunities and challenges."□This commentary is well written, supported with relevant references and offer a good and concise insight into the current treatment options as well as proposed new studies.

**Answer:** We thank very much for the reviewer's comment.

**Reviewer 3:**

(1) This manuscript is very interesting. The Authors describes the complex and various use of the adjuvant chemotherapies after surgical treatment of pancreatic cancer. The analysis of this topic is complete, mainly based on the evaluation of the paper of Conroy and also based on other valuable studies. In summary the study is well written. I have only one suggestion. In my opinion should be necessary to insert in the Title the word "Commentary": for example "Modified Folfirinox for resected pancreatic cancer: opportunities and challenges-Commentary on Conroy's study" ..

**Answer:** We appreciate the reviewer's comment and suggestion. The manuscript type of our paper is Field of Vision, which has specific format requirements. The manuscript begins with "Commentary on Hot Topics ...". Therefore, we kept the original title.

Thank you for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

*Feng Yang*  
*Department of Pancreatic Surgery,*  
*Huashan Hospital, Shanghai Medical College,*  
*Fudan University, Shanghai*  
Fax: +8621-52888277  
E-mail: yffudan98@126.com